The causative molecular event in chronic myeloid leukemia (CML) is the genetic transposition of ABL and BCR sequences to form a BCR-ABL fusion gene, leading to the expression of a constitutively active tyrosine kinase. 1 Inhibition of BCR-ABL Kinase activity with the small molecule drug imatinib (IM) results in a rapid hematologic response and has revolutionized the therapy of CML patients. 2 Resistance to IM is a growing clinical problem, resulting in many cases from the acquisition of mutations in the BCR-ABL kinase domain (KD). Detection of specific mutations directs changes in management such as the use of new tyrosine kinase inhibitors or stem cell transplantation. For this reason, periodic genotyping of the BCR-ABL KD to screen for drug-resistant mutations may play an important role in the management of CML patients. 3 We developed a sensitive and quantitative high-throughput assay using SEQUENOM MassARRAY system that enables fast and reliable detection of mutations in the BCR-ABL KD.
One hundred and two cDNA samples obtained from peripheral blood of 40 patients diagnosed with Philadelphiapositive CML were analyzed, 26 patients had chronic phase, 10 accelerated and four blast crisis CML. Twenty-nine patients were IM resistant (mean disease duration 47 months) and 11 were IM intolerant (mean disease duration 28 months).
MassARRAY genotyping was carried out using a chip-based matrix-assisted laser desorption-time-of-flight mass spectrometer ( Figure 1a ) (Sequenom, San Diego, CA, USA). Multiplex SNP assays were designed (Supplementary File 1 online) (Mass-ARRAY assay design v 3.0, Sequenom) for 27 previously reported different mutations that confer IM resistance ( Table 1) . The reactions were carried out according to the manufacturer's instructions 4 ( Figure 1b) . The BCR-ABL KD mutational status was also determined by direct sequencing as previously C1308T  T315I  2  C1106G  L248V  16  C1308A  T315N  3   a   G1113A  G250E  17   a   C1315G  F317L  4  G1112A  G250R  18  T1392C  M343T  5  G1120C  Q252H  19  T1416C  M351T  6  G1120T  Q252H  20   a   T1439G  F359V  7   a   T1121C  Y253H  21  T1440G  F359C  8  A1122T  Y253F  22  G1499A  V379I  9  G1127A  E255K  23  T1508C  F382L  10  A1128T  E255V  24   a   T1523A  L387M  11  A1191G  D276G  25  G1525C  L387F  12  A1194G  T277A  26  A1551C  H396P  13  T1230C  V289A  27  A1551G  H396R  14  T1295C  F311L a Detected mutations.
b Mutation was identified in two different patients.
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Figure 1
Identification of the BCR-ABL KD mutations using MALDI-TOF mass spectrometry. (a) Homogenous mass EXTEND (hME) assay outline. The assay involves PCR amplification of the region containing the mutation of interest (G1113A) (A1), SAP treatment to remove excess dNTPs, addition of DNA polymerase along with a mixture of di-deoxy and deoxy NTPs that allows extension of the hME primer through the mutation site and generates allele-specific extension products (A2), clean-up of the extension reaction to remove salt, spotting of the extension product into 384 SpectroCHIPs and the analysis of the spotted product using the MALDI-TOF mass spectrometry (A3). (b) BCR-ABL G250E (G1113A) mutation detection. Total RNA and genomic DNA were simultaneously extracted from blood samples and complementary DNA (cDNA) was synthesized. PCR amplification of the region containing the G1113A mutation was carried using 10 ng of DNA and 50 ng of cDNA as templates in 384-well plate. Post-PCR treatment by shrimp alkaline phosphates to prevent future incorporation of unused dNTPs was followed by single primer extension reaction (hME assay) to generate diagnostic products based on their unique mass values. Following this step, MassExtend clean resin (Sequenom) was added to the mixture to remove extraneous salts that could interfere with the MALDI-TOF analysis. Genotyping was determined by robotically spotting 15 nl of each extension product onto silicon chip preloaded with propriety matrix (SpectroCHIP; Sequenom), which was subsequently read by the MALDI-TOF mass spectrometer. Representative spectra showing (B1) no template control reaction, black arrow-head indicates the unincorporated extension primer; (B2) wild-type allele (G1113), empty arrow-head indicates the wild-type allele; (B3) Mutant allele (G1113A) in cDNA sample, black arrow indicates the mutant allele; (B4) mutant allele (G1113A) in the corresponding DNA sample, black arrow indicates the mutant allele. (c) Direct sequencing validation. The MALDI-TOF mass spectrometry results were confirmed by direct sequencing. The upper reading frame: wild-type sequence (G1113). Lower reading frame: mutated sequence (A1113) of the representative BCR-ABL transcript. (d) Quantitative analysis. A quantitative analysis of DNA mixtures with variable ratios between G1113 (wild type) and A1113 (mutation) template was preformed. The relative mutation load can be estimated by dividing the peak intensity of the mutated allele by the peak intensity of the wild-type allele. published 5 ( Figure 1c) . Seven mutations, all previously reported, were identified by MassARRAY genotyping, all of them in IMresistant patients and none in IM-intolerant patients (Table 1) . Of note, one IM-resistant patient harbored two different mutations simultaneously. Moreover, all seven mutations were also detected using genomic DNA as template (Figure 1b) . The direct DNA sequencing data were consistent with the mass spectrometry results and confirmed the same seven mutations. 
